Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > GBM

<< Previous

Bullboard Posts

Next >>

Comment by N0taP00pon Sep 28, 2023 9:32am

184 Views

Post# 35658966

RE:GBM

DJDawg: What's your estimate of timeline for GBM? Non-GLP and GLP have no diagnostic or therapeutic goals other than safety assessment, correct? Maybe limited therapeutic goals during non GLP animal studies. Then an early phase 1 to establish dosage, then actual phase1, 2, 3, etc.. I'm thinking 5-6 years, going by history vs wishful thinking . What's your take. The majority owners of TLT probably know this and that's why the stock hasn't moved much. Only a BTD for current study will solve that problem.

DJDawg wrote:
GBM is a good choice for next target as the limited treatment options and rapid mortality makes it one of the conditions that is prioritized by review bodies such as Health Canada.

It would not be difficult to recruit patients for a one and done type trial as there are many patients with limited options for treatment at this time.

All in all, if they have money at some point, they could move faster on this than past efforts (I hope).